Haohai Biotech announced that on September 7, 2026, the company repurchased 65,500 H shares through the Hong Kong Stock Exchange, accounting for 0.0291% of the total number of H shares issued before the incident. The repurchase price range for each share was HK$16.57 to HK$16.85, with a total cost of HK$1.0963 million. All of the shares repurchased will be cancelled. The share repurchase authorization for this repurchase was reviewed and approved on May 29, 2026. The total number of H shares authorized to be repurchased was 3.478 million. As of the completion of the repurchase, a total of 721,000 H shares had been repurchased, accounting for 2.073% of the total number of H shares issued on the date the authorization was approved.

Haohai Biotech announced that on September 7, 2026, the company repurchased 65,500 H shares through the Hong Kong Stock Exchange, accounting for 0.0291% of the total number of H shares issued before the incident. The repurchase price range for each share was HK$16.57 to HK$16.85, with a total cost of HK$1.0963 million. All of the shares repurchased will be cancelled. The share repurchase authorization for this repurchase was reviewed and approved on May 29, 2026. The total number of H shares authorized to be repurchased was 3.478 million. As of the completion of the repurchase, a total of 721,000 H shares had been repurchased, accounting for 2.073% of the total number of H shares issued on the date the authorization was approved.